2022
DOI: 10.3389/fphar.2022.890748
|View full text |Cite
|
Sign up to set email alerts
|

Predicted Vancomycin Dosage Requirement in Patients With Hematological Malignancies and Dosage Dynamic Adjustment

Abstract: Purpose: The purpose of this study was 1) to predict the requisite vancomycin daily dose (Dvan) used in the target patients suffering from both bacterial infection and hematological malignancies and 2) to construct a vancomycin-dose-graphical tool to assist clinicians to develop vancomycin dosing regimens and further 3) to establish a programming process for vancomycin dynamic dosage adjustment to help clinicians to adjust vancomycin dosing regimens according to physiological and pathogenic factors of the targ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

2
2

Authors

Journals

citations
Cited by 4 publications
(7 citation statements)
references
References 41 publications
0
7
0
Order By: Relevance
“…Consequently, there may be an increase in resistance and a failure to respond to treatment, which can result in a higher rate of infection-related morbidity and mortality. Despite the fact that systemic inflammatory response syndrome and malignancy may both be risk factors for the development of vancomycin-associated AKI, this phenomenon and its causal consequences have rarely been considered in most studies ( Song and Wu, 2022 ). These results suggest that early monitoring of vancomycin concentration in these patients may be critical for maintaining desired effects without the occurrence of side effects.…”
Section: Discussionmentioning
confidence: 99%
“…Consequently, there may be an increase in resistance and a failure to respond to treatment, which can result in a higher rate of infection-related morbidity and mortality. Despite the fact that systemic inflammatory response syndrome and malignancy may both be risk factors for the development of vancomycin-associated AKI, this phenomenon and its causal consequences have rarely been considered in most studies ( Song and Wu, 2022 ). These results suggest that early monitoring of vancomycin concentration in these patients may be critical for maintaining desired effects without the occurrence of side effects.…”
Section: Discussionmentioning
confidence: 99%
“…PK/PD and TDM (or C T-SS ) were used to build the CDM based on the concentration models derived from our earlier research ( Song and Wu, 2022 ); real-world data derived from 21 retrospective cases were applied to assess the superiority and performance of CDM in clinical efficacy prediction by comparison to the current frequently-used dose model (FDM), and based on the availability of TDM, the strategy of CDM-driven individualized, dynamic, and full-course dose prediction for VAN therapy was formulated. Based on CDM and using Monte Carlo simulation, VAN dosages in empirical therapy were predicted for six Staphylococci populations [i.e., Staphylococcus aureus ( S. aureus ), Staphylococcus epidermidis ( S .…”
Section: Methodsmentioning
confidence: 99%
“…This may cause a significant deviation between the predicted and desired dose due to the fact that VAN is often delivered via multiple intermittent infusion (MII) rather than via i.v. bolus, and the simplified AUC model is not well-suited for MII ( Song and Wu, 2022 ). Therefore, the dose derived from these calculators is not necessarily a true personalized dose.…”
Section: Introductionmentioning
confidence: 99%
“…Note: (1) These equations were built based on steady state and one-compartment intravenous infusion model, (2) Equation 1 and 2 are derived and modified from our previous studies ( Song et al, 2021 ; Song and Wu, 2022 ) and Equation 3 from the published literatures ( Jeurissen et al., 2011 ; Rybak et al., 2020b ).…”
Section: Methodsmentioning
confidence: 99%